CDT Equity

CDT Equity Liabilities

The The Liabilities of CDT Equity (CDT) as of Oct 22, 2026 is 2.28 B USD. In the previous year, The Liabilities was 10.99 M USD — a change of 20,646.38% (higher).

Liabilities

2.28 BUSD

YoY

20,646.38%

Last updated:

In 2025, CDT Equity's total liabilities amounted to 2.28 B USD, a 20,646.38% difference from the 10.99 M USD total liabilities in the previous year.

The CDT Equity Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2021
192,506.00 USD
Jan 1, 2022
10.09 M USD
Jan 1, 2023
7.68 M USD
Jan 1, 2024
10.99 M USD
Jan 1, 2025
2.28 B USD
The CDT Equity Liabilities history
YEARLiabilitiesYoY
2.28 BUSD+20,646.38%
10.99 MUSD+43.03%
7.68 MUSD-23.91%
10.09 MUSD+5,143.47%
192,506.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CDT Equity Stock analysis

What does CDT Equity do? CDT Equity Inc generates revenue through the development and commercialization of clinical assets targeting unmet medical needs. The company focuses on disease-agnostic life science solutions, with key assets including AZD1656, a glucokinase activator for diabetes mellitus and Hashimoto’s Thyroiditis treatment, and AZD5904, a myeloperoxidase inhibitor for idiopathic male infertility. These assets are licensed for use in autoimmune diseases, immunodeficient conditions, and specific medical applications like uveitis, preterm labor, and renal transplant rejection. Pharmaceutical companies and healthcare providers purchase these clinical assets for research and therapeutic development. The company’s revenue streams derive from licensing agreements and commercial partnerships for its pipeline products. AZD1656 is positioned as a treatment option for Hashimoto’s Thyroiditis and Graves’ disease, while AZD5904 targets idiopathic male infertility. The firm’s focus on autoimmune and immunodeficient conditions aligns with healthcare providers seeking innovative therapies for complex patient populations. Licensing deals with pharmaceutical firms drive the primary revenue model. CDT Equity Inc’s business model centers on developing and licensing clinical assets across multiple therapeutic areas. Its pipeline includes AZD1656 for diabetes and thyroid conditions, and AZD5904 for infertility and autoimmune disorders. The company collaborates with healthcare providers and pharmaceutical partners to advance these assets toward commercialization, generating income through licensing fees and future product sales. CDT Equity is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing CDT Equity's Liabilities

CDT Equity's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating CDT Equity's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing CDT Equity's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

CDT Equity's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in CDT Equity’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about CDT Equity stock

The Liabilities of CDT Equity is 2.28 B USD in 2025.

The Liabilities of CDT Equity changed from 10.99 M USD to 2.28 B USD, representing a 20,646.38% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities CDT Equity since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's CDT Equity historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — CDT Equity

All Key Metrics — CDT Equity